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Abstract 
Gestational diabetes mellitus [GDM] is a condition associated with glucose intolerance first diagnosed during 
pregnancy. Over the years, there has been an increase in prevalence of women with gestational diabetes; 
resulting to increasing studies on this type of diabetes. Genetic studies on GDM,  reveals its association with 
genes such as Glucokinase- GCK, Variable Number Tandem Repeats on Insulin gene-INS-VNTR. Certain 
factors predisposes an individual to GDM, which includes: Body Mass Index or body weight, ethnic group/race, 
age. Various complications such as macrosomia, hyperinsulinemia, nerve palsies and fetal mortality has been 
associated with GDM. While it has been observed that most women with GDM, later developed postpartum 
type 2 diabetes. Presently, the management and treatment involves diet modification, exercise and use of 
hypoglycaemic agents. 
Keywords: Body Mass Index [BMI]; Gestational Diabetes Mellitus [GDM]; Insulin Receptor Substrate -1 [IRS-
1]; Insulin resistance. 
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1. Introduction 
Gestational diabetes mellitus [GDM] is any form of glucose intolerance first diagnosed during pregnancy [1]. 
This indicates that women with gestational diabetes were never diagnosed of having diabetes before conception.  
As a result of this, clinicians recommend Oral Glucose Tolerance Test [OGTT] for women during gestation. 
This test is normally conducted between the  24-28th week of gestation [2]. A threshold of 135mg/dL 
[7.5mmol/L] was recommended by the American College of Obstetricians and Gynaecologists, especially in 
women with high risk of GDM [1]. 
A previous study in 1990, showed the prevalence of GDM to occur in about 10% of all pregnant women [3]. 
Various reviews show an increased prevalence of GDM from 10-100% with respect to the race or the ethnic 
group, thereby posing a major concern to health practitioners around the globe [4-8].   With this increasing 
prevalence, certain questions arises; such as: who is at a risk of gestational diabetes? Are there gene(s) involved 
in predisposition to this condition? What effect(s) does environmental factors have on gene expression? 
2. Evidences for genetic factors 
There are various genetic factors which could predispose a woman to gestational diabetes, these factors include: 
ethnic group, health history, previous delivery of a macrosomic baby and the presence of certain genes. 
2.1. Ethnic group  
Individuals belonging to races or ethnic groups such as Hispanic-America, Native-America, South-East Asia, 
Africa and Australia are more predisposed to gestational diabetes than others. This deduction was due to 
observed  increase in prevalence of GDM among these races [9-11]. A study conducted in 1999 on the Canadian 
population [Quebec], showed that there was a high prevalence of GDM among Cree women [12]. 
A further study was conducted in the same year on 394 Cree women and 788 non-natives. Their results showed  
that 11.4% of Cree women had GDM when compared with 5.3% of non-native women [13].   The researchers in 
[13] attributed this difference to be due to high obesity among Cree women. Thereby increasing their 
predisposition to GDM. Therefore, within these ethnic groups some women who seem “normal” might have an 
undiagnosed pre-diabetes before gestation.  
2.2. Health and gestational history 
Women with previous diagnosis of prediabetes are highly predisposed to gestational diabetes, when compared to 
women with normal plasma glucose level; This is as a result of higher than normal plasma glucose level, which 
is not high enough to be refered to as diabetes [2, 14]. Therefore, in the presence of certain environmental 
factors such as hormonal interactions during gestation; gestational diabetes could result. An individual with first 
degree parents having diabetes, could be predisposed to GDM [2]. Thereby increasing the likelihood of 
inheriting polymorphic or mutant genes (PPARγ2-PRO12Ala,INS VNTR and GCK genes) which could 
predispose such an individual to either type 1, type 2 or gestational diabetes [11].   
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Alernatively, previous delivery of a baby with a weight of 4.0kg or more increases the risk of gestational 
diabetes[2]. Macrosomia resulting from GDM, indicates that there was an over-expression of certain placental 
hormones [15]. Therefore, there is a probability that such hormones would be overexpressed in subsequent 
pregnancies.  In addition, women with history of GDM in a previous pregnancy are at a higher risk of 
developing it again in subsequent pregnancies. 
2.3. Gene/genotypic analyses 
Researches are being carried out to observe the association between genes responsible for predisposition to type 
1, type 2 diabetes and GDM [11, 16]. Some of the genes studied include: INS VNTR, HLA-DQB1 and GCK 
genes.  
2.3.1. INS VNTR, PPARγ2 and HLA-DQB1 genes 
The insulin hormone is coded for by the INS gene. Study on the INS gene showed the presence of a variable 
number tandem repeat about 0.5kb upstream of the INS gene. The VNTR was found to be about 15bp long, 
consisting of the sequence ACAGGGGTCTGGGG, though there could be slight variation in the repeat 
sequences [16]. It has been observed that the INS gene expression is determined by the number of polymorphic 
VNTR repeats [17]. Some studies have shown  the possibility of an association between  INS gene, type 1 and 
type 2 diabetes [18-20]. Besides the INS gene, another gene which has been studied is the HLA-DQB1 gene; 
which plays an important role in immune system regulation and an increased risk of type 1 diabetes [11]. 
Furthermore studies on this gene have shown that women with a family history of diabetes had a high frequency 
of  polymorphic HLA-DQB1 alleles responsible for diabetes [11]. The PPARγ2- (peroxisome proliferative-
activated receptor-gamma -2) is a transciption factor, which regulates lipid storage and glucose metabolism [21]. 
It influences the expression of certain genes necessary for glucose metabolism by binding to specific promoter-
regions of these genes [21]. An example of such polymorphism is PPARγ2-PRO12Ala [22]. 
A study was carried out in 2004, to observe the genotypic differences in diabetic gene (INS VNTR, HLA-DQB1 
and GAD65Ab) association between Arabian and Scandinavian women with GDM. In this study they observed 
a total of 500 women with GDM (400 Scandinavian and 100 Arabian) and 550 women non-GDM (428 
Scandinavian and 122 Arabian). The results of their research showed that Arabian women with GDM were 50% 
more insulin resistant when compared with Scandinavian women of the same BMI; while the Scandinavian 
women with GDM had a higher frequency of HLA-DQB1 gene than the corresponding Arabian women [11]. In 
addition, they observed that both groups of women with GDM had a higher frequency of GAD antibodies 
(GAD65Ab) than women with normoglycaemia. Futhermore, their study on Insulin gene variable number 
tandem repeat –INS VNTR and peroxisome proliferator-activated receptor-gamma 2 –PPARγ2-PRO12Ala 
polymorphism in both groups  (between the GDM and non-GDM women) revealed no significant differences in 
the frequencies of these genes. These findings implies that predisposition to GDM could be detected by testing 
for GAD65Ab. While the differences in frequencies for insulin resistance and HLA-DQB1, were due to racial 
differences which might have resulted from variations in gene pool between the two populations. In addition, 
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this also deduces that there would be a higher prevalence of type 1 diabetes and GDM among the Scandinavian 
population, when compared with the Arabian population. 
2.3.2.Glucokinase [GCK] gene mutations 
A Glucokinase enzyme catalyzes the phosphorylation of glucose to glucose-6-phosphate. In addition to this, it 
plays an important role in carbohydrate metabolism, by acting as a glucose sensor for the pancreas, liver and 
brain [23]. The glucokinase enzyme is coded for by the GCK gene. Therefore, a mutation in the GCK gene 
would result in an alteration in the glucokinase enzyme produced [24].   
A study was conducted in the United Kingdom by [25]; they observed 15 GDM women, from which some had 
GDM in previous pregnancies. Their results showed that 12 (80%) of 15 subjects used had mutations in their 
glucokinase genes. The following mutations were found K161+2del15, N180K, R191W, Y215X and L288-1G-
> A. The mutation in L288-1G->A is a frameshift mutation, while that of Y215X was found to be a nonsense 
mutation.  Contrary to these findings, a similar research carried out on the Brazilian population yielded a 
completely different result. In which they screened 200 women (100-: GDM with good glycaemic control and 
100-: non-GDM) for mutations in the GCK gene [26]. They observed that only 13 women out of the 200 (6.5%) 
subjects used for the study had GCK gene mutations. They detected a new mutation-: intron3 (c.43331A>G), 
while the others found were intron 6 (c.47702T>C, rs2268574), intron 9 (c.48935C>T, rs2908274) and exon 10 
(c.49620G>A, rs13306388). Therefore, the researchers in [26], concluded that there were no associations 
between the mutations they observed and GDM. Considering these two findings, the reason for the observation 
in [25], could have been as a result of the sample size (15 subjects); with respect to that of [26] in which 200 
subjects were utilized. In addition, the GCK gene mutations associated with GDM could vary from one 
population to the other resulting from variations in the gene pool which could be responsible for the disparities 
observed. 
3. Environmental factors influencing gestational diabetes  
The phenotypic expression observed is often times determined by the genotypic composition, but there are 
instances in which the phenotypic expression of a gene is modified by certain environmental factors. With 
respect to this, the expression of GDM in certain women could be influenced by some environmental factors. 
Such as: 
3.1.  Body weight 
A pre-gestation Body Mass Index [BMI] of about 25kg/m2 or more increases predisposition to GDM when 
compared to women with normal BMI [2, 27].  In [28] a study was carried out to observe the effect of 
pregestation BMI and risk of GDM using 1644 women. They observed that women with BMI >29kg/m2 were at 
a very high risk of GDM, when compared to women with low, normal or overweight BMI [28]. They further 
observed that women who had a pregestation weight gain of ≥10kg in adulthood, were three times more likely to 
develop GDM compared with women who gained ≤2.5kg.  Therefore, this implies that pregestation body weight 
has an influence on gestational body weight, which invariably increases the risk of GDM; unless lifestyle and 
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diet management is advised and ensured. In addition, studies have proven the probability of a relationship 
between gestational weight gain in early pregnancy and gestational diabetes.  A study conducted by [29], 
compared the weight gain in the early pregnancies of two groups of women (345-women with GDM and 800-
control); they observed that women with high rate of gestational weight gain in early pregnancy are at a high 
risk of GDM [29].  Another research was done by [9], in which they observed the correlation between BMI and 
GDM taking into consideration 5 races (Asian, Filipina, Hispanic, white non-Hispanic and African-American). 
They observed that at normal BMI (22-24.9kg/m2), there was a GDM prevalence of about 8.0 and 9.9% among 
the Asian and Filipina women; when compared with the other races, which had a  prevalence of  >8.0% in only 
overweight and obese women with BMI >28kg/m2. A critical evaluation of these findings, indicates that 
pregravid increase in  BMI is a high risk for GDM, especially if such an individual is genetically predisposed to 
GDM or belongs to a high risk ethnic group. The molecular explanation for this is still being studied. 
Researchers believe that an accumulation of  fatty acid (overweight and obese individuals) can trigger insulin 
resistance [30].  It has been found that in the presence of ATP and Long chain Acyl CoA synthetase, fatty acids 
can be converted to Long chain Acyl CoA and Diacylglycerol. Which has the ability to activate serine/threonine 
kinases. These kinases phosphorylates Insulin Receptor Substrate-1 (IRS-1), leading to a decrease in 
phosphatidylinositol (P13-kinase) activation complex. Thereby, preventing the insulin=IRS-1 complex, resulting 
to insulin resistance and GDM [31-33]. Therefore, this explains why increase in BMI would invariably lead to 
increased pre-disposition to GDM. 
3.2.  Age 
Women who are above 25 years and still reproducing are highly predisposed to GDM, which occur as a result of 
decreased production of insulin due to increasing age [2, 10]. 
3.3. Hormonal factors 
During pregnancy the foetus derives its glucose from the mother through the placenta; this action by the foetus 
could result to maternal hypoglycaemia. Therefore, in order to prevent this, certain placental hormones undergo 
several interactions, which is directed at preventing hypoglycaemia. Some of these interactions could result to 
insulin resistance in the mother. One of such Studies have shown that overexpression of Tumor Necrosis Factor-
Alpha (TNF-α), which is a placental hormone; would lead to serine phosphorylation of placental insulin 
receptors (IRS-1), thereby altering it [34]. Normally, IRS-1 forms a complex with phosphatidylinositol (P13) 
kinase, which then facilitates the addition of insulin molecule to the insulin receptor substrate. Unfortunately, 
the serine phosphorylation of the IRS-1, hinders the formation of the enzyme=substrate complex; leading to the 
inability of insulin to bind to the substrate known as Insulin Resistance [35]. 
4. Resultant effects of GDM on foetal and neonatal health 
Maternal insulin resistance would result in the inability of cells to absorb glucose for energy metabolism, 
storage and an increased concentration of plasma glucose.  Thereby, leading to an increase in the concentrations 
of triglycerides, fatty acids, cholesterol and protein in circulations [36]. These increased plasma glucose, 
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triglycerides and amino acids could be passed to the foetus through the placenta [37]. Which invariably requires 
an increased secretion of insulin by the foetus; in order to facilitate the absorption and utilization of glucose, 
triglycerides and amino acids. Consequently, these results in abnormal increase in growth and fat deposits; 
leading to macrosomia, perinatal mortality, polycythemia and other birth defects [27,38,39]. 
 In addition, maternal  overexpression of placental hormones (Leptin and TNF-α), would result in the activation 
of phospholipase A2 (which is a lipolytic enzyme that catalyzes the conversion of alpha linolenic acid -ALA to  
docosahexanoic acid –DHA, a type of omega-3-polyunsaturated fatty acid). Therefore overexpression of 
placental hormones, leads to accumulation of omega-3-polyunsaturated fatty acid in the foetus. Resulting in 
excessive foetal adiposity known as Macrosomia [40]. 
Alternatively, inability of maternal cells to absorb glucose would result to over utilization of fat for energy 
metabolism; thereby leading to increased production of  ketones. Which if when passed to the foetus, could 
cause Diabetes Ketoacidosis; resulting in foetal mortality [41-42]. 
In addition, post-natal studies have shown that children from GDM mothers, had a higher BMI compared to 
their peers; which is due to over-accumulation of glucose and fat deposits during intra-uterine growth [27].  
5. Resultant effects of GDM on maternal health 
Women with GDM are more likely to undergo caesarean section, due to the macrosomic size of the baby [43]. 
Often times, women with GDM develop type 2 diabetes after delivery [44, 47]. A postnatal study conducted 
between 1971 and 2003, involved observing and monitoring 5470 GDM women and 783 non-GDM subjects 
[45]. The result of the observation showed that 7.2% of the GDM subjects developed postpartum type 2 diabetes 
compared with 2.0% of the control. This implies that women who develops GDM during gestation are more 
likely to develop postpartum  type 2 diabetes. 
6. Treatment and management of GDM 
Just like other types of diabetes, GDM is presently being treated and managed through diet modification, 
exercise and pharmacological methods. 
6.1 Diet modification 
Nutrition therapy should be encouraged and ensured through the help of a dietician or a nutrition counselor. This 
helps to guide the indivdual in the type and quantity of food intake with respect to BMI [2]. Studies have shown 
how restriction of daily calorie to approximately 25kcal/kg can reduce hyperglycaemia in obese women having 
BMI 30kg/m2 or more [46]. Thereby, reducing the predisposition to developing GDM. In addition, diet 
modification could also help delay or prevent postpartum type 2 diabetes. 
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6.2 Exercise 
In addition, exercise or intensive lifestyle has been found to delay the onset of type 2 diabetes in women with 
GDM [47]. As recommended by [44], an individual with a history of GDM should undergo about 30 minutes 
exercise daily in order to enhance glucose metabolism and weight loss. A study by [47] showed a 50% reduction 
in the progression of GDM to type 2 diabetes in GDM subjects who were involved in a combination of an 
intensive lifestyle and metformin; when compared with GDM subjects administered with placebo. The result 
from this study explains that intensive lifestyle would help GDM individual maintain a normal BMI, thereby 
reducing the risk of developing type 2 diabetes. 
6.3. Pharmacological methods 
The treatment of GDM using pharmacological methods need to be handled with high importance. As any 
suitable hypoglycaemic agent must not be able to pass through the placenta to the foetus, in order to prevent 
foetal hyperinsulinemia [44]. In addition, the hypoglycaemic agent should be used with caution, by ensuring 
regular/daily monitoring of blood glucose levels, in order to avoid an overdosage [2]. Various studies have been 
carried out on the different types of hypoglycaemic agents, which were suitable in managing the GDM; but 
further studies needs to be done to ascertain whether it passes through the placenta. One of such studies is that of 
[48], in which they observed the effectiveness of insulin aspart in maintaining a normal postprandial blood 
glucose in GDM, when compared with other types of insulin derivatives (regular exogenous human insulin and 
endogenous human insulin). Despite the effectiveness of the insulin aspart, its effect(s) on the foetus was not 
stated or ascertained. 
7. Summary and prospects 
Increasing  prevalence of GDM in high-risk population and its expression among low-risk; indicates its need for 
utmost attention. Other forms through which the condition can be managed and treated should be explored, 
taking into consideration the health of the foetus. In addition, early detection and screening among high-risk 
population, would be a guide to monitoring, managing and preventing the condition. 
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